TD Cowen analyst Ritu Baral has maintained their bullish stance on NGNE stock, giving a Buy rating on November 13.
Claim 50% Off TipRanks Premium and Invest with Confidence
- Unlock hedge-fund level data and powerful investing tools designed to help you make smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis so your portfolio is always positioned for maximum potential
Ritu Baral’s rating is based on several positive developments surrounding Neurogene’s ‘401 program. The recent Phase 1/2 data for ‘401 demonstrated consistent and durable improvements across multiple domains, suggesting that ‘401 could be a leading treatment option. A significant majority of patients met the responder criteria for the EMBOLDEN trial, surpassing the expected success rate, which is a promising indicator for the upcoming Phase 3 results. Additionally, the ‘401 treatment was found to be safe and well-tolerated, with no severe adverse events reported.
Financially, Neurogene appears to be in a strong position, with a cash runway expected to last until the first quarter of 2028. This financial stability supports continued development and potential commercialization of ‘401. The combination of promising clinical data and a solid financial foundation underpins Ritu Baral’s Buy rating for Neurogene’s stock.
According to TipRanks, Baral is a top 100 analyst with an average return of 32.3% and a 57.03% success rate. Baral covers the Healthcare sector, focusing on stocks such as ACADIA Pharmaceuticals, Palvella Therapeutics, and Avidity Biosciences.